PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening.

Lee, Jangsoon; Liu, Huey; Pearson, Troy; Iwase, Toshiaki; Fuson, Jon; Lalani, Alshad S; Eli, Lisa D; Diala, Irmina; Tripathy, Debu; Lim, Bora; Ueno, Naoto T

Lee, Jangsoon; Liu, Huey; Pearson, Troy; Iwase, Toshiaki; Fuson, Jon; Lalani, Alshad S; Eli, Lisa D; Diala, Irmina; Tripathy, Debu; Lim, Bora; Ueno, Naoto T.

Afiliación

Lee J; Section of Translational Breast Cancer Research, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Liu H; Section of Translational Breast Cancer Research, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Pearson T; Section of Translational Breast Cancer Research, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Iwase T; Section of Translational Breast Cancer Research, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Fuson J; Section of Translational Breast Cancer Research, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Lalani AS; Puma Biotechnology, Inc., Los Angeles, CA 90024, USA.
Eli LD; Puma Biotechnology, Inc., Los Angeles, CA 90024, USA.
Diala I; Puma Biotechnology, Inc., Los Angeles, CA 90024, USA.
Tripathy D; Section of Translational Breast Cancer Research, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Lim B; Section of Translational Breast Cancer Research, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ueno NT; Section of Translational Breast Cancer Research, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Biomedicines ; 9(7)2021 Jun 28.

Article en En | MEDLINE | ID: mdl-34203351

Palabras clave

HER2-positive breast cancer; RNAi screening; neratinib; synergistic effect; triple-negative breast cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies / Screening_studies Idioma: En Revista: Biomedicines Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google